EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Alnylam Pharmaceuticals's enterprise value is $36,495 Mil.
Alnylam Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $2,348 Mil. Therefore, Alnylam Pharmaceuticals's EV-to-Revenue for today is 15.54.
The historical rank and industry rank for Alnylam Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
ALNY'
s EV-to-Revenue Range Over the Past 10 Years
Min: 8.49 Med: 46.21 Max: 200.54
Current: 15.54
During the past 13 years, the highest EV-to-Revenue of Alnylam Pharmaceuticals was 200.54. The lowest was 8.49. And the median was 46.21.
ALNY's EV-to-Revenue is ranked worse than 65.53% of 998
companies
in the Biotechnology industry
Industry Median: 7.38
vs ALNY: 15.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alnylam Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Alnylam Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's EV-to-Revenue falls into.
Alnylam Pharmaceuticals's current Enterprise Value is $36,495 Mil.
Alnylam Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,348 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals's share price for today is $285.56.
Alnylam Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALNY has been successfully added to your 